Thursday, 26 March 2026 03:25 AM
Earnings
STOCKHOLM, SE / ACCESS Newswire / March 26, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2025.
The Annual Report for the financial year 2025 is available on the company's website: https://vicorepharma.com/investors/financial-reports/
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [email protected]
Hans Jeppsson, CFO, tel: +46 70 553 14 65, [email protected]
About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com
This information is information that Vicore Pharma Holding is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-26 08:00 CET.
Attachments
Vicore Annual Report 2025
SOURCE: Vicore Pharma Holding